» Articles » PMID: 39066345

Modeling 1-Cyano-4-Dimethylaminopyridine Tetrafluoroborate (CDAP) Chemistry to Design Glycoconjugate Vaccines with Desired Structural and Immunological Characteristics

Abstract

Glycoconjugation is a well-established technology for vaccine development: linkage of the polysaccharide (PS) antigen to an appropriate carrier protein overcomes the limitations of PS T-independent antigens, making them effective in infants and providing immunological memory. Glycoconjugate vaccines have been successful in reducing the burden of different diseases globally. However, many pathogens still require a vaccine, and many of them display a variety of glycans on their surface that have been proposed as key antigens for the development of high-valency glycoconjugate vaccines. CDAP chemistry represents a generic conjugation strategy that is easily applied to PS with different structures. This chemistry utilizes common groups to a large range of PS and proteins, e.g., hydroxyl groups on the PS and amino groups on the protein. Here, new fast analytical tools to study CDAP reaction have been developed, and reaction conditions for PS activation and conjugation have been extensively investigated. Mathematical models have been built to identify reaction conditions to generate conjugates with wanted characteristics and successfully applied to a large number of bacterial PSs from different pathogens, e.g., , Paratyphi A, Enteritidis, Typhimurium, and . Furthermore, using Paratyphi A O-antigen and CRM as models, a design of experiment approach has been used to study the impact of conjugation conditions and conjugate features on immunogenicity in rabbits. The approach used can be rapidly extended to other PSs and accelerate the development of high-valency glycoconjugate vaccines.

Citing Articles

Development and Characterization of a 13-Plex Binding Assay to Detect Antibodies in Human Samples.

Vezzani G, Mancini F, Raso M, Giannelli C, Nappini R, Gasperini G Open Forum Infect Dis. 2024; 11(12):ofae675.

PMID: 39660019 PMC: 11630041. DOI: 10.1093/ofid/ofae675.


Design of a Glycoconjugate Vaccine Against Paratyphi A.

Alfini R, Carducci M, Massai L, De Simone D, Mariti M, Rossi O Vaccines (Basel). 2024; 12(11).

PMID: 39591175 PMC: 11599127. DOI: 10.3390/vaccines12111272.

References
1.
Perepelov A, Shekht M, Liu B, Shevelev S, Ledov V, Senchenkova S . Shigella flexneri O-antigens revisited: final elucidation of the O-acetylation profiles and a survey of the O-antigen structure diversity. FEMS Immunol Med Microbiol. 2012; 66(2):201-10. DOI: 10.1111/j.1574-695X.2012.01000.x. View

2.
Berti F, De Ricco R, Rappuoli R . Role of O-Acetylation in the Immunogenicity of Bacterial Polysaccharide Vaccines. Molecules. 2018; 23(6). PMC: 6100563. DOI: 10.3390/molecules23061340. View

3.
Lees A, Nelson B, Mond J . Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents. Vaccine. 1996; 14(3):190-8. DOI: 10.1016/0264-410x(95)00195-7. View

4.
. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399(10325):629-655. PMC: 8841637. DOI: 10.1016/S0140-6736(21)02724-0. View

5.
Micoli F, Giannelli C, Di Benedetto R . O-Antigen Extraction, Purification, and Chemical Conjugation to a Carrier Protein. Methods Mol Biol. 2020; 2183:267-304. DOI: 10.1007/978-1-0716-0795-4_14. View